

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION

IN RE NATIONAL PRESCRIPTION

OPIATE LITIGATION

*This document relates to:*

Track One Cases

MDL 2804

Case No. 17-md-2804

Hon. Dan Aaron Polster

**EXHIBIT LIST**  
**(Corrected)**

<b>Exhibit Number</b>	<b>Description</b>	<b>Date</b>
1.	Rafalski, James E., Expert Report: <i>Analysis of Distributor and Manufacturer Regulatory Compliance to Maintain Effective Controls for the Prevention of Diversion of Controlled Substances</i>	04/15/2019
2.	McCann, Craig J., PH.D., CFA, Supplemental Expert Report	04/03/2019
3.	Keller, Lacey R., Expert Analysis Report	04/15/2019
4.	Rannazzisi, Joseph T., Deputy Assistant Administrator, Office of Diversion Control, U.S. DOJ, DEA Letter re: registrants	09/27/2006
5.	Gitchel, G. Thomas, Acting Chief, Diversion Operations Section, Letter re: registrants	05/16/1984
6.	Rannazzisi, Joseph T., Deputy Assistant Administrator, Office of Diversion Control, U.S. DOJ, DEA Letter re: registrants	12/27/2007
7.	Transcript of the Deposition of Colleen McGinn	12/24/2018

8.	Transcript of the Deposition of Joseph Tomkiewicz	11/28/2018
9.	DEA Diversion Investigators Manual	
10.	Transcript of the Deposition of Thomas Prevoznik (Vol. II)	04/18/2019
11.	Transcript of the Deposition of Jennifer R. Norris	08/07/2018
12.	Transcript of the Deposition of Nathan J. Hartle	07/31/2018
13.	DEA's Office of Diversion Control's 13 <sup>th</sup> Pharmaceutical Industry Conference Presentation and Attendance List	09/2007
14.	DEA's Office of Diversion Control's 13 <sup>th</sup> Pharmaceutical Industry Conference Agenda	09/2007
15.	DEA's Office of Diversion Control's 13 <sup>th</sup> Pharmaceutical Industry Conference Agenda and Presentation by Michael Mapes regarding Suspicious Orders	09/2007
16.	Email from Tracey Hernandez to Diane Miranda, et al. regarding DEA/Industry Conference Report	09/26/2007
17.	Settlement and Memorandum of Agreement between the Department of Justice, DEA, and Walgreens Co.	06/10/2013
18.	Appendix A to the Settlement and Memorandum of Agreement between the Department of Justice, DEA, and Walgreens Co.	
19.	Appendix B to the Settlement and Memorandum of Agreement between the Department of Justice, DEA, and Walgreens Co.	
20.	Transcript of the Deposition of Thomas G. Schoen	09/05/2018
21.	Whitelaw, Dr. Seth B., Expert Report, Examination of Compliance Standards for Opioid Manufacturers and Distributors	04/15/2019
22.	Kinsey, R.Ph, MBA, Sandra K.B., Amended Expert Report	06/03/2019
23.	Verdict Form, United States of America v. Gurry, et al.	05/02/2019

24.	First Superseding Indictment, United States of America v. Babich, et. Al.	10/24/2017
25.	McCann, Ph.D., CFA, Craig J., Second Supplemental Expert Report	04/15/2019
26.	Exhibit 33 of S. Becker's Deposition: DEA Press Release re Harvard's suspension	06/15/2010
27.	Exhibit 36 of S. Becker's Deposition: DEA Notice of Decision & Order regarding Masters	09/15/2015
28.	Exhibit 38 of S. Becker's Deposition: Press Release regarding KeySource license suspension	06/10/2011
29.	Exhibit 37 of S. Becker's Deposition: DOJ Press Release regarding civil penalty levied against Cardinal	12/23/2016
30.	Exhibit 35 of S. Becker's Deposition: DOJ Press Release re Value Drug settlement	06/25/2014
31.	Administrative Memorandum of Agreement between U.S. Department of Justice, Drug Enforcement Administration, Mallinckrodt plc and Mallinckrodt LLC	07/20/2017
32.	Transcript of the Deposition of John Gillies	02/07/2019
33.	Exhibit 33 of K. Harper's Deposition: Email from Karen Harper to Michael J. Santowski regarding Controlled Substance Suspicious Order Monitoring Program Training for Executive Committee Presentation	04/12/2011
34.	Transcript of the Deposition of Karen Harper	01/15/2019
35.	Buzzeo, R.Ph., Ronald W. Expert Report	05/31/2019
36.	Transcript of the Deposition of James Rausch	11/15/2018
37.	Mallinckrodt DEA Compliance Procedure, Controlled Substance Suspicious Order Monitoring Draft 2	05/13/2008
38.	Suspicious Order Monitoring Program No. C/S Comp 3.0	10/29/2010

39.	Rannazzisi, Joseph T., Deputy Assistant Administrator, Office of Diversion Control, U.S. DOJ, DEA Letter to Mallinckrodt, Inc. re: registrants	12/27/2007
40.	SOM Team Activity Log	
41.	Memorandum from Howard Davis to Karen Harper, Suspicious Order Monitoring Program No. C/S Comp 3.0	11/02/2010
42.	Email from Karen Harper to Jim H. Rausch, cc: George R. Saffold regarding SOM Program	06/09/2010
43.	Email from Karen Harper to John Adams <i>et al.</i> regarding Suspicious Order Monitoring Training Notes from Bulk Narcotic Sales Meeting Presentation	06/06/2008
44.	Transcript of the Deposition of William Ratliff	12/19/2018
45.	Excel Spreadsheet showing National Account Manager bonus payments	2006-2011
46.	Transcript of the Deposition of Kate Neely	01/08/2019
47.	Meeting Notes from Buzzeo DEA Conference	10/27-30/2008
48.	Email from Karen Harper to Eileen Spaulding regarding SOM	09/24/2010
49.	Email from Gail Tetzlaff to Jennifer Buist and Eileen Spaulding regarding NAMs clearing orders	03/02/2012
50.	Email from Victor Borelli to Brenda Rehkop, cc: Karen Harper, et al. regarding NAMs clearing orders	07/15/2011
51.	Email from Bill Ratliff to James Rausch <i>et al.</i> regarding Propoxyphene Napsylate orders for Sovereign	09/03/2008
52.	Email from Steven Becker to Karen Harper <i>et al.</i> regarding Old Bridge account	10/28/2008
53.	Email from Victor Borelli to Kate Muhlenkamp regarding customer sale expansion	11/14/2008

54.	Email from Victor Borelli to James Rausch regarding Peculiar order report	04/23/2010
55.	Emails from Steven Becker to Penny Myers and James Rausch regarding HD Smith	05/05/2010
56.	Email from Victor Borelli to Brenda Rehkop <i>et al.</i> regarding customer high demand for oxycodone	06/23/2010
57.	Email from Bill Ratliff to Kate Muhlenkamp <i>et al.</i> regarding Oxycodone orders	06/04/2008
58.	Email Chain Between Victor Borelli and Steve Cochran regarding Oxy 30	01/27/2009
59.	Email from Cathy Stewart to Bill Ratliff and Karen Harper regarding Sunrise Wholesale	05/30/2008
60.	Email from Victor Borelli to Steve Cochrane regarding things	05/20/2008
61.	Transcript of the Deposition of Victor Borelli	11/29/2018
62.	Transcript of the Deposition of Ginger Collier	01/08/2019
63.	Exhibit 15 of G. Collier's Deposition: Email from Ginger Collier to Steven. Becker and Victor Borelli regarding Oxy Sales by retailer	11/19/2010
64.	Exhibit 16 of G. Collier's Deposition: Summary of customers sourcing more than 2 distributors for Oxy 30	09/2010
65.	Email from Wayne Corona to Karen Harper regarding cut-off pharmacies	10/20/2011
66.	Brooks Pharmacy Monthly Total 15mg & 30mg Oxy "Sales Qty Govt UOM" 2010-2011 Chart	2010/2011
67.	Transcript of the Deposition of Steven A. Becker	12/19/2018
68.	Chargeback Data	1998-2018
69.	Email from Karen Harper to self regarding adding chargeback data analysis to the SOM program	11/18/2010

70.	Exhibit 21 to K. Harper's Deposition: Email from Jeff Burd to Vince Kaiman, cc: Robert Lesnak et al. regarding Methadone	04/17/2007
71.	Exhibit 15 to S. Becker's Deposition: Harvard (MI) Summary of orders	
72.	Email from G. R. Green to James Lang regarding SOP	02/03/2000
73.	Audit Committee Meeting Presentation: Controlled Substance Orders Responsibility for Knowing Our Customers	06/20/2007
74.	Transcript of the Fact Deposition of Stephen Seid (Vol I)	12/12/2018
75.	Transcript of the Fact Deposition of Stephen Seid (Vol II)	12/13/2018
76.	SOP – System to Disclose Suspicious Orders of Controlled Substances	03/12/2003
77.	Email from Dan Colucci to Howard Udel, et al. regarding SOP 7.7 System to Disclose Suspicious Orders of Controlled Substances	06/06/2007
78.	Email from Stephen Seid to ValueTrak regarding Approval of Item Exceeding Average	07/13/2009
79.	Email from Stephen Seid to ValueTrak regarding Approval of Item Exceeding Average	07/13/2009
80.	Email from Stephen Seid to Dawn Wargo regarding Approval of Item Exceeding Average	07/20/2009
81.	Email from Stephen Seid to FFSOrderMngt regarding Approval of Item on Order Exceeding Average	09/09/2009
82.	Email from Stephen Seid to FFSOrderMngt regarding Approval of Item on Order Exceeding Average	09/24/2009
83.	Email from Stephen Seid to FFSOrderMngt regarding Approval of Item on Order Exceeding Average	10/27/2009
84.	Email from Stephen Seid to FFSOrderMngt regarding Approval of Item on Order Exceeding Average	10/01/2009

85.	PPLPC004000344802	
86.	Purdue Distribution Service Agreements	03/23/2009
87.	Abrams, Robin, VP, Assoc. Gen. Counsel, Purdue, Order Monitoring System HDMA Presentation	03/13/2012
88.	SOP 7.7 System to Disclose Suspicious Orders [PPLPC004000119321]	06/06/2007
89.	Email from Gregory Bogdan to Steven Projansky regarding Fee for Service SOP	01/14/2013
90.	Inventory Data License Agreement between Walgreen Co. and Purdue Pharma, L.P.	2010
91.	Inventory Data License Agreement between Walgreen Co. and Purdue Pharma, L.P.	2012
92.	Transcript of the Deposition of Jack Crowley	01/10/2019
93.	Transcript of the 30(b)(6) Deposition of Stephen Seid	12/12/2018
94.	Report to OMS Team	
95.	PPLP004035073-7	
96.	Purdue Distribution Service Agreements	10/15/2002
97.	Transcript of the Deposition of Mark Geraci	04/04/2019
98.	Buzzeo Cegedim PDMA Compliance Solutions Report	09/25/2012
99.	McGinn, Colleen Suspicious Order Monitoring Presentation	
100.	Transcript of the Deposition of Kevin Kreutzer	11/27/2018
101.	Suspicious Order Monitoring, DEA Order Holds	08/01/2014
102.	Suspicious Order Monitoring, Customer Due Diligence	
103.	Suspicious Order Monitoring, Customer Site Visits	08/01/2014
104.	Suspicious Order Monitoring, DEA Order Holds	08/01/2014

105.	Suspicious Order Monitoring, Do Not Ship List	08/01/2014
106.	Suspicious Order Monitoring, DEA Order Holds, Locations Other than Britain, PA and North Wales, PA	10/01/2015
107.	TEVA Suspicious Order Monitoring, DEA Order Hold Policy SOP-8277	06/18/2018
108.	TEVA Suspicious Order Monitoring, Do Not Ship List, SOP-8278	06/18/2018
109.	TEVA Suspicious Order Monitoring, Customer Due Diligence, SOP-8279	06/18/2018
110.	TEVA Suspicious Order Monitoring, Customer Site Visits, SOP-8280	06/18/2018
111.	Tomkiewicz, Joseph, DEA Compliance Manager, SOM and Current Cases Presentation	2017
112.	DEA and SOM Internal Audit Report	08/19/2015
113.	Kevin Kreutzer, Manager, SOM Letter to DEA regarding Suspicious Order Report	02/13/2013
114.	Teva Suspicious Order Report Analysis	01/16/2019
115.	TEVA SO Reports to DEA	
116.	Responses And Objections of Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, LTD., Actavis, LLC, Actavis Pharma, Inc., and Watson Laboratories, Inc. to Plaintiffs' Third Set of Interrogatories	01/07/2019
117.	Transcript of the Deposition of Paul Campanelli	03/21/2019
118.	Chart regarding Total Pills/Units Shipped by Endo	1999-2017
119.	Transcript of the Deposition of Stephen C. MacRides	03/15/2019
120.	Transcript of the Deposition of Lisa Walker	12/04/2018



121.	Email from Tara Chapman to Maryann Holovac regarding Request to move Opana ER NDA 21-610 to the Orange Book Discontinued List	05/31/2012
122.	FDA News Release, FDA Requests Removal of Opana ER for Risks Related to Abuse	06/08/2017
123.	Email from John Bullock to Lisa Walker and Sal Grausso regarding Opana ER – Cardinal Refuses to Order	06/12/2017
124.	Email from MaryJo Magrone to Sal Grausso, et al. regarding Pricing Proposal Submission – OPANA ER Wholesaler Promotion approval	08/30/2017
125.	Email from JMPage to Lisa Walker, et al. regarding Opana Transition	08/31/2017
126.	Endo Sales Data Chart	
127.	Email from Paul Evans to Jeremy Tatum regarding 100507 Qualitest Overview Presentation	05/2010
128.	Par's Sales Profit Chart	2008-2015
129.	Transcript of the Deposition of Tracey L. Norton	01/16/2019
130.	Risk Management Plan for Opioid Analgesics Focus on : Oxycodone ER	02/19/2004
131.	Risk Minimization Action Plan for Opana ER	06/2007
132.	Endo Pharmaceuticals Meeting with DEA Presentation	09/30/2003
133.	Email from Bob Barto to Sue Tolen regarding Revised DEA Meeting Minutes [ENDO-OPIOID_MDL-01706006-011}	10/02/2003
134.	Par's and Endo's Responses concerning SOM Program [PAR_OPIOID_MDL_0001596408]	
135.	Email from Lisa Walker to Michael Kalady regarding Endo (Branded) Products Renewal Applications and SOM Policy	05/13/2018

136.	Email from Neil Shusterman to Mark Collins regarding Opana ER Risk Management – SOM Program	10/29/2013
137.	Email from Neil Shusterman to Harris Rotman, et al. regarding SOM White Paper	02/01/2017
138.	SOMS Program Update Presentation	11/07/2013
139.	Summary of Teleconference with UPS regarding SOMS	02/13/2013
140.	Correspondence from Tracey Hernandez, Larry Shaffer, DEA Compliance to Kim Liddel, RA Supervisor, UPS Supply Chain regarding Review of UPS SOM Activities	11/06/2013
141.	UPS SCS Suspicious Order Monitoring Program Summary	11/12/2009
142.	Email from Kim Lindell to Lisa Walker regarding getting to you your customers	04/11/2014
143.	ENDO-OPIOID_MDL-0000369517	
144.	ENDO-OPIOID_MDL-01334119-124	
145.	Summary of SOM Program, Process Flow	
146.	Annual Training Curriculum Review and Approval for Required Training	2012
147.	Qualitest Audit Report	09/04/2008
148.	Qualitest Report regarding Review of Order Monitoring Program	06/18/2009
149.	Email from Tracey Hernandez to Sanjay Patel enclosing Action Items from Tablets DEA Deficiency Letter	01/04/2013
150.	Email from Larry Shaffer to Eric Brantley enclosing SOMS Violations and Presentations	10/07/2013
151.	Email from Tracey Hernandez to Sanjay Patel enclosing Action Items from Tablets DEA Deficiency Letter	01/04/2013

152.	Email from Aimee Cooper to Heather Jones enclosing Memorandum regarding Manufacturers Briefing with Qualitest	03/27/2013
153.	Email from Tracey Hernandez to Jill Cornell regarding DEA Compliance Initiative Presentation	02/09/2013
154.	Email from Denise Hudson to Tracey Hernandez, et al. regarding DEA Inspection Wrap-Up in Charlotte	11/16/2011
155.	Email from Keith Margolis to William Price and Carol Sherman regarding Bellco - Qualitest SOMS Letter and Questionnaire	02/27/2014
156.	Email from Eric Brantley to Heather Jones regarding SOPs for SOM	04/21/2015
157.	Email from Tracey Hernandez to Jill Connell regarding DEA Compliance Initiatives Program Presentation	02/09/2013
158.	Email from Eric Brantley to Jill Miller regarding SOM	
159.	PAR_OPIOID_MDL_0000020898	
160.	Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc.'s Supplemental Objections and Responses to Plaintiff's Interrogatories	03/04/2019
161.	ENDO-HSGAC_0010368	
162.	Email from Eric Brantley to Tracey Hernandez enclosing Qualitest SOM Update Presentation	04/17/2014
163.	Email from Eric Brantley to Tracey Hernandez enclosing Revised SOM Advisory Board Charter	02/25/2014
164.	Email from Jason Ehrlinspiel to Tracey Hernandez regarding Notice of Civil Violations	09/30/2014
165.	PAR_OPIOID_MDL_0000399716	
166.	PAR_OPIOID_MDL_0001615738	
167.	PAR_OPIOID_MDL_0002102288	

168.	Email from Jason Ehrlinspiel to Tracey Hernandez regarding Notice of Civil Violations	09/30/2014
169.	Email from Joseph Barbarite to Angela Feniger et al enclosing Par Pharmaceutical Audit Report from DEA Consultants	05/13/2010
170.	Email from Angela Feniger to Patricia Lipari regarding SOM and enclosing Par Pharmaceutical, Inc. Standard Operating Procedure	06/21/2012
171.	Email from Angela Feniger to Joseph Barbarite et al enclosing DEA Audit Report	07/15/2015
172.	Email from Angela Feniger to Heather Jones et al regarding Cedegim for all Par Orders SOM)	03/22/2016
173.	Par Pharmaceutical, Inc. Standard Operating Procedure Form	
174.	Transcript of the Deposition of Michele R. Dempsey (Vol. I)	01/22/2019
175.	Email from Mike Bulone to Michael Szwarc et al regarding CSOS Update and presentation	03/17/2013
176.	Bacco, Guy, Janssen Overview Presentation	
177.	Optimizing Chronic Pain Management with Duragesic	
178.	JAN-MS-04199587	
179.	Email from Michele Dempsey to Terrance Woodworth regarding SOM Questionnaire for JOM Distributors	12/04/2017
180.	JOM Customer Service Suspicious Order or Excessive Narcotic Orders Work Instruction	
181.	JOM Customer Service Order Processing of Controlled Substance Work Instruction	
182.	JOM Customer Service Schedule II-V Order Processing and Investigating Suspicious or Excessive Narcotic Orders Standard Operating Procedure	

183.	JOM Customer Service Suspicious or Excessive Orders Work Instruction	07/24/2013
184.	Email from Luis Valcarcel to Ron Kuntz and Paul Lowman regarding NUCYNTA Trade Plans, enclosing High level overview of JOM CII and SOM Process	06/25/2012
185.	Suspicious Order Monitoring Workshop	12/13/2017
186.	Transcript of the Deposition of Michele R. Dempsey (Vol. II)	03/08/2019
187.	Controlled Substances Suspicious Order Monitoring Program Questionnaire	
188.	Email from Michele Dempsey to Debbie Sniscak regarding Recommendations	01/23/2018
189.	Email from Valerie Chikwendu to Michele Dempsey regarding Controlled Substances Project	
190.	Email from Michele Dempsey to Marc Larkins regarding Draft change to SOM Report for JOM	
191.	Managed Market Summit, Trade Analytics Presentation	10/18/2012
192.	Email from Michele Dempsey to Robert Martin regarding DEA Serves a Suspension Order on Walgreens Distribution Center in Jupiter, FL - JOM Review of Data	09/24/2012
193.	Evaluation of the SOM System for Johnson & Johnson Presentation	
194.	Email from Ron Kuntz to Patricia Yap regarding SOM Contact and Meeting Notes	06/17/2013
195.	SOM Benchmarking with Purdue Meeting Notes	03/20/2012
196.	Email from Jack Crowley to Michele Dempsey enclosing notes regarding Janssen Abuse and Diversion Detection	07/26/2013
197.	Janssen Pharmaceuticals Inc Abuse and Diversion Detection Program, Prescribers of Concerns Notes	07/23/2013

198.	Email from Terrance Woodworth to Brian Strehlke enclosing draft SOM Report for JOM	02/06/2018
199.	Excel spreadsheet regarding ordering pattern	
200.	Email from Michael Levitt to Theresa Hoffman regarding 6 Order on the SOM Report	03/26/2015
201.	Email from Michael Levitt to Kristina Bezares regarding 1 Order on the SOM Report for Oct. 3, 2014	10/03/2014
202.	Email from Michael Levitt to Theresa Hoffman regarding 2 Orders on SOM Report for Nov. 26, 2014	11/26/2014
203.	Email from Michael Levitt to Raffaella Figliano regarding 1 Suspicious & Excessive Order for Apr. 14, 2016	04/15/2016
204.	Email from Michael Levitt to Raffaella Figliano regarding 1 Suspicious & Excessive Order for Apr. 20, 2016	04/20/2016
205.	Email from Michael Levitt to Raffaella Figliano regarding 1 Suspicious & Excessive Order for Apr. 27, 2016	04/27/2016
206.	Email from Belinda Corum to Denise Moran regarding 2 suspicious/excessive for Dec. 8, 2016	12/08/2016
207.	Email from Belinda Corum to Roxanne Covino regarding 1 suspicious and excessive order for Aug. 26, 2016	08/29/2016
208.	Email from Michele Dempsey to SeWha Park and Phil West regarding McKesson agreement to pay \$150m settlement	01/18/2017
209.	Administrative Memorandum of Agreement between the U.S. DOJ, DEA and Cardinal Health, Inc.	2012
210.	Email from Mike Kaufmann to Gary Dolch, et al. regarding In the Penalty Box	01/21/2008
211.	Operation One Cardinal Health Quality Management Meeting: Opportunity Team Presentations	01/13-14/2005
212.	Drug Distribution Compliance Budget Review	2007

213.	CAH_MDL_PRIORPROD_DEA07_00884713	
214.	Email from Mark Hartman to Steve Reardon regarding Threshold system and customer issues	01/28/2008
215.	Settlement and Release Agreement and Administrative Memorandum of Agreement between U.S. DOJ, DEA and Cardinal Health, Inc.	2008
216.	Email from Mark S. Mitchell to Cassi Baker and Steve Reardon regarding Drug Wholesale Advisory Council	05/12/2005
217.	Email from Michael Mone to Mark Hartman regarding Possible Suspect Pharmacy	01/07/2008
218.	Transcript of the Deposition of Steve Reardon	11/30/2018
219.	Cegedim's Findings and Recommendations on Cardinal Healthcare's SOM System	01/23/2008
220.	Investigation Report of the Special Demand Committee, BOD of Cardinal Health, Inc.	04/12/2013
221.	Email from Carolyn McPherson to Nicholas Rausch regarding revised instructions for Deloitte enclosing Procedure for Threshold Limit Determination for Drug Family - Phase 2	01/08/2008
222.	Transcript of the Deposition of Mark Hartman	11/15/2018
223.	Hartman, Mark, Supply Chain Integrity Presentation	11/06/2008
224.	Email from Scott Sopher to Michael Deloso regarding the situation at CAH remains chaotic	10/17/2012
225.	Morford, Craig, 2012 Annual Quality and Regulatory Report to the Audit Committee of the BOD	11/02/2012
226.	ValueCentric Webpage	
227.	DEA Baltimore District Office Presentation on Cardinal Health Swedesboro Distribution Center	

228.	Cardinal Health, Inc.'s FOIL Appeal Letter to Steve Krantz, Esq., Assistant Attorney General for the State of New York	09/27/2006
229.	Transcript of the Deposition of Todd Cameron	09/26/2018
230.	Transcript of the Deposition of Donald Steven Morse	12/13/2018
231.	Expert Report of Brian Reise	05/31/2019
232.	Cardinal Health's Responses to Plaintiffs' Second Notice of Deposition Pursuant to Rule 30(b)(6)	10/25/2018
233.	Cardinal Health's Second Supplemental Responses to Plaintiffs' Second Notice of Deposition Pursuant to Rule 30(b)(6)	04/16/2019
234.	Purdue SOP [PPLPC004000344799]	01/14/2013
235.	Email re McKesson Contracts [ENDO-OPIOID_MDL-01056072]	03/18/2013
236.	Administrative Memorandum of Agreement between U.S. DOJ, DEA and McKesson Corp.	2017
237.	McKesson Drug Operations Manual	
238.	Transcript of the Deposition of Gary Hilliard	01/10/2019
239.	McKesson Corp.'s Second Supplemental Objections and Responses to Plaintiffs' Combined Discovery Requests	03/04/2019
240.	Email from Dave Gustin to Tyra Williams regarding Variance and Suspicious Reports	02/04/2011
241.	Transcript of the Deposition of Blaine M. Snider	11/08/2018
242.	Memorandum regarding Meeting Between the Office of Diversion Control and McKesson Corp. on January 3, 2006	01/23/2006
243.	McKesson Operations Manual for Pharma Distribution, Lifestyle Drug Monitoring Program	



244.	Boggs, Gary, State of Prescription Drug Abuse Presentation	
245.	Letter from McKesson Corp.'s Counsel to Linden Barber, Esq., Associate Chief Counsel of DEA regarding Order to Show Cause	04/25/2007
246.	Transcript of the Deposition of William de Gutierrez-Mahoney	11/28/2018
247.	Email from Alexandra Feigel to Diane Martin regarding November LDMO	12/10/2007
248.	McKesson U.S. Pharma - DEA Licensure Audit, Lifestyle Drug Program	07/27/2007
249.	Settlement and Release Agreement and Administrative Memorandum of Agreement between U.S. DOJ, DEA and McKesson Corp.	05/02/2008
250.	Email from Cathy Scofield to Tracy Jonas et al enclosing CSMP Sales Training Presentation	03/10/2008
251.	Email from Gregory Carlson to Pharmacy Team Leader regarding 440 Met its max of Oxycondone APAP for the month	06/24/2010
252.	RNA - Threshold Change/Level 1 Firm	2009
253.	Step II, Consent Agreement between Gary Evan Sivak, M.D. and The State Medical Board of Ohio	
254.	Email from Donald Walker to Bill de Gutierrez-Mahoney regarding New DEA Ordering Standards	04/17/2008
255.	U.S. DOJ, DEA Letter regarding Registration Consequences for McKesson Corp. for Violations of the Controlled Substances Act	11/04/2014
256.	Email from Dave Gustin to Dave Fagerskog et al regarding gaps between the amount of Oxy or Hydro allowed to be purchase and amount needed	08/31/2011

257.	Email from Nate Hartle to Krista Peck regarding threshold reduction initiative report	05/01/2015
258.	McKesson's CSMP Oxycodone Threshold Reduction Report	02/09/2015
259.	Email from Micheal Bishop to Jenna Smith regarding DEA Threshold Warning Report	04/03/2013
260.	Email from Michael Oriente to Dave Gustin et al regarding CSMP contribution, DCM call, and tightening up our increase process	04/15/2011
261.	Email from Tom McDonald re Threshold Change Requests	07/27/2012
262.	Email from Jennifer Melvin re: South CSMP Distribution Contacts and Level 1 calls	08/02/2011
263.	Email sent on behalf of Don Walker re implementing an enhanced SOM Program with attachments and webex invite	10/24/2013
264.	Letter from DOJ to McKesson Re: Possible Civil Action Against McKesson Corporation for Violations of the Controlled Substances Act	08/13/2014
265.	Transcript of the Deposition of Donald Walker	01/10/2019
266.	RNA- Threshold Change/Level 1 Forms for CVS	04/08/2010
267.	Threshold Change Forms for various Accounts and Emails from Dave Gustin to Micheal Bishop asking him to increase thresholds	11/28/2008
268.	CVS CSMP: Threshold Review	01/09/2009
269.	Threshold Change request for Giant Eagle approval	10/29/2010
270.	Threshold Change Request for Giant Eagle, Threshold was increased 30% every 2w since 01/14/2009	02/23/2009
271.	Threshold Change Form for Giant Eagle approval	12/17/2008

272.	Threshold Change Form Approvals for Giant Eagle	12/19/2008
273.	Threshold Change Form Approval for Giant Eagle	11/21/2008
274.	Threshold Change Form Approvals for Giant Eagle	07/31/2008
275.	Threshold Change Form Approvals for Giant Eagle	10/22/2008
276.	Threshold Change Form Approvals for Giant Eagle and an Email form Dave Gustin noting they need to know why the stores are purchasing well past historic trends	05/28/2008
277.	Email from Gary Hilliard to Sharon Mackarness Re: Hydrocodone Reports	10/23/2006
278.	Email from Timothy Foster to Joe Lumpkin, et al, Re: CSCP Tracker	11/01/2013
279.	Email from David Graziano to Melenie Petropoulos and Stephen Schmidt re: CSCP Trackers Marc's 2WA and 39MA	12/23/2013
280.	Email from Stephen Schmidt to Melenie Petropoulos and others re: Marc's CSCP Threshold Report	01/27/2014
281.	MCKMDL00478912	
282.	MCKMDL00478913	
283.	McKesson Corporation Board of Directors' Response to International Brotherhood of Teamsters	
284.	Controlled Substance Monitoring Program	06/24/2008
285.	Email from Dan Jefferies to Nate Hartle and others RE: Opioid Reductions	01/30/2017
286.	Email from Donald Walker re: List 1 Chemicals and Clarifying the "partial" Issue in CSMP	06/03/2010
287.	SOMs Process Flow[ENDO-OPIOID_MDL-01334119]	04/00/2014
288.	Abuse and Diversion Detection [PPLP004035073]	09/00/2015
289.	ABC Diversion Control Program effective June 25, 2007	06/25/2007

290.	Carlos Aquino Expert Report	06/06/2019
291.	Transcript of the Deposition of Chris Zimmerman	08/03/2018
292.	Chemical Handler's Manual, A Guide to Chemical Control Regulations	
293.	Deposition Transcript of Eric Cherveney	11/09/2018
294.	Deposition Transcript of Stephen Mays (Vol. I)	10/24/2018
295.	Deposition Transcript of Stephen Mays (Vol. II)	02/08/2019
296.	ABC's Diversion Control Program	08/07/2017
297.	Order to Show Cause and Immediate Suspension of Registration sent to Amerisource Bergen	04/19/2007
298.	Settlement and Release Agreement	06/22/2007
299.	Reported to DEA Report for Opioid Items for all OHIO Summit County Customers from 2007-2013	
300.	ABDCMDL00308070	
301.	Email from Eric Cherveney to Stephen Hendrickson and others re: CSRA 590 Validation Project	08/05/2016
302.	Transcript of the Deposition of David May	08/04/2018
303.	Transcript of the Deposition of Candace Harbauer	02/19/2019
304.	Mary Woods Deposition Transcript	01/10/2019
305.	Prescription Supply, Inc. Controlled Substances Policy/Procedure	01/21/2015
306.	Transcript of the Deposition of James Schoen	02/27/2019
307.	Transcript of the Deposition of Kirk Harbauer	02/27/2019
308.	Letter to Cardinal Health from DEA to reiterate the responsibilities of controlled substance manufacturers and distributors to inform DEA of suspicious orders	12/27/2007

309.	State of Ohio Board of Pharmacy Written Response to Prescription Supply, Inc	10/25/2017
310.	Transcript of the Deposition of Jeff Abernathy	11/15/2018
311.	Transcript of the Deposition of Susanne Hiland	01/23/2019
312.	SOM Reddwerks Upgrade - US Compliance	
313.	Portfolio Scoring Worksheet – Suspicious Order Monitoring	
314.	Plaintiffs’ Responses to the Amended and Clarified Discovery Ruling 12 Supplemental Interrogatory Issued to Plaintiffs	01/25/2019
315.	Transcript of the 30(b)(6) Deposition of Walmart, through the testimony of Susanne Hiland	01/22/2019
316.	Transcript of the Deposition of Ramona Sullins	01/04/2019
317.	Emails re: WalMart Drug Tracking	06/17/2015
318.	Walmart Inc.’s Responses to Plaintiffs (First) Combined Discovery Requests to National Retail Pharmacies Defendants	11/30/2018
319.	Emails re: DEA agents at store DC 6028	09/15/2014
320.	Walmart Pharmacy Manual, Evaluating Orders of Interest and Suspicious Order Reporting	09/30/2014
321.	Controlled Substance Risk Assessment: Executive Summary	
322.	WMT_MDL_000048100 - WMT_MDL_000048101	
323.	Suspicious Order Monitoring Program Policy and Procedures for the Pharmaceutical Integrity Team	
324.	Settlement and Memorandum of Agreement	06/10/2013
325.	Transcript of the Deposition of Edward Bratton	12/16/2018
326.	Handling Suspicious Drug Orders	02/15/2005

327.	DEA Letter re: a proposed system of detecting and reporting excessive orders	12/27/1988
328.	Letter from DEA re: a regulatory investigation of Walgreens	05/17/2006
329.	Emails regarding Suspicious Transactions and the DEA	03/02/2006
330.	DEA Suspicious Controlled Drug Report	04/03/2007
331.	Walgreens Second Supplemental Responses to Plaintiffs' (First) Combined Discovery Requests	02/19/2019
332.	Transcript of the Deposition of Eric Stahmann	10/16/2018
333.	Deposition Errata for E. Bratton	03/05/2019
334.	Settlement and MOA	06/10/2013
335.	Walgreens Order to Show Cause and Immediate Suspension of Registration	09/13/2012
336.	DOJ Subpoena	02/04/2013
337.	Emails re: Weekly PMO Status - Thursday Update	02/15/2013
338.	Perrysburg CIII-CV - meeting notes Email	03/01/2013
339.	Letter to DEA re Subpoena	02/20/2013
340.	CII orders to be shipped from Amerisource Bergen	03/2014
341.	CII orders to be shipped from Amerisource Bergen	03/2014
342.	Emails re Suspicious Controlled Drug Orders	08/03/2010
343.	Shipment contents from Walgreens Perrysburg DC and DEA Audit	02/28/2013
344.	Shipment contents from Walgreens Perrysburg DC and DEA Audit	02/28/2013
345.	Email RE: Suspicious Orders	06/27/2007

346.	Chemical Handler's Manual, A Guide to Chemical Control Regulations	01/31/2004
347.	Walgreens Distribution Center follow up letter to March 2006 regulatory investigation	07/28/2006
348.	Suspicious Order Reporting	03/26/2008
349.	Office of Diversion Control - Knowing your Customer/Suspicious Orders Reporting	03/28/2013
350.	DEA Compliance - Perrysburg Distribution Center	12/22/2008
351.	Withheld Due to Privilege	
352.	RX Questionable Order Qty	12/11/2006
353.	Transcript of the Deposition of Douglas Peterson	12/20/2018
354.	Transcript of the Deposition of Christopher Domzalski	01/17/2019
355.	Authentication of Prescription Order Policy	10/07/2013
356.	Transcript of the Deposition of Deb Bish	02/01/2019
357.	Transcript of the Deposition of Jennifer Diebert	01/24/2019
358.	Update on Rx Supply Chain Contingency Plan for Jupiter	04/06/2012
359.	DEA Suspicious Order Reporting	06/23/2008
360.	Emails re: CSR Version Summary	10/08/2012
361.	Controlled Substance Order Review	
362.	Transcript of the Deposition of Tasha Polster	01/23/2019
363.	WAGMDL00245768	
364.	WAGMDL00325129	
365.	Email re: Suspicious Order	02/05/2013
366.	Email re: Transferring Controlled Substances	04/11/2013

367.	Email re: Oxycodone no longer being ordered via PDQ	09/28/2012
368.	DEA Suspicious Order Item Limits - Phase II	08/26/2009
369.	July 2011 DEA Statistics	07/2011
370.	Transcript of the Deposition of Barbara Martin	01/25/2019
371.	Walgreens's Second Amended Objections and Responses to Plaintiffs' First Set of Interrogatories	03/04/2019
372.	Emails re: High Quantity Stores	01/10/2011
373.	WAGFLDEA00000846	
374.	WAGMDL00436802	
375.	Emails re: High Quantity Stores	01/10/2011
376.	Emails re: Proposed org chart	12/16/2012
377.	Transcript of the Deposition of Steven Mills	11/08/2018
378.	Emails re: Controlled Substance Order Quantity Override Form	08/19/2013
379.	Emails re: Ceiling Update	01/03/2103
380.	Emails re: Shrink Set	04/16/2013
381.	Email re: VAWD Question - Inventory Controls Questionable Regular RX Orders	05/11/2011
382.	CVS-MDLT1-000060805	
383.	Expert Report of Craig J. McCann	03/25/2019
384.	CVS-MDLT1-000060798	
385.	Transcript of the Deposition of Mark Vernazza	11/20/2018
386.	Exhibit 30 to the Deposition of Mary Woods	
387.	Transcript of the Deposition of Amy Propatier	11/29/2018



388.	Opti- Source Oxy Orders [Acquired_Actavis_00665233]	03/24/2011
389.	Deposition Transcript Excerpts of Ellen Wilson	01/24/2019
390.	Order on SOM Report [JAN-MS-03739793]	07/21/2015
391.	Order Management System [PPLP003430436]	03/23/2009
392.	Transcript of the Deposition of Sherri Hinkle	01/25/2019
393.	DEA Comments [CAH_MDL2804_02489191]	06/04/2008
394.	Transcript of the Deposition of Aaron Burtner	01/17/2019
395.	Transcript of the Deposition of Terrence Dugger	01/23/2019
396.	Draft Summary of DEA-HDMA Meeting [CAH_MDL2804_02489188]	04/15/2008
397.	Draft HDMA Best Practices for Controlled Substances [HDA_MDL_000148607]	01/31/2008
398.	Chronology of HDMA DEA Involvement [HDA_MDL_000081364]	10/31/2016
399.	Chronology of HDMA DEA Involvement [HDA_MDL_000081363]	10/31/2016
400.	Transcript of the Deposition of Gary Millikan	01/11/2019
401.	Industry Compliance Guidelines [HDA_MDL_000145918]	11/14/2008
402.	DEA Suspicious Orders [HDA_MDL_000213078]	05/07/2008
403.	HDMA DEA Suspicious Order Best Practices [HDA_MDL_000213058]	02/12/2008
404.	HDMA Report [HDA_MDL_000213229]	01/31/2008
405.	Transcript of the Deposition of Shauna Helfrich	01/10/2019
406.	HDMA Report [HDA_MDL_000213212]	01/31/2008
407.	Emails re: SOM Presentation	01/15/2014

408.	Member Questionnaire [HDA_MDL_000139414]	01/17/2008
409.	Customer Verification Procedure [HDA_MDL_000150198]	01/10/2008
410.	DEA Org Chart and SO Check [HDA_MDL_000151104]	01/02/2008
411.	Business Idea Description – Control Drug IRR update	
412.	Rite Aid Distribution Center DEA Regulatory Guidelines	
413.	Controlled Drug Above Average Order Monitoring Program	02/28/2010
414.	Rite Aid’s Objections and Responses to Plaintiffs’ First Set of Combined Discovery Requests	11/30/2018
415.	Transcript of the Deposition of Janet Getzey Hart	01/30/2019
416.	Transcript of the Deposition of Marian Wood	01/24/2019
417.	Transcript of the Deposition of Christopher Belli	12/20/2018
418.	Transcript of the Deposition of Janet Getzey Hart	01/31/2019
419.	Emails re: Rite Aid CSMP	09/12/2011
420.	Transcript of the Deposition of Debra Chase	01/04/2019
421.	Threshold Exception List	04/18/2011
422.	Above Threshold July 2012	08/06/2012
423.	Project Initiation for 5046 Suspicious Order Monitoring	10/02/2013
424.	HBC Service Company’s Amended Responses to Plaintiffs’ First Set of Combined Discovery Requests	
425.	Emails re: DSCSA Documents with attachments	12/04/2014
426.	Transcript of the Deposition of Matthew Rogos	02/22/2019
427.	HBC Service Company’s Supplemental Answers to Plaintiffs’ First Set of Interrogatories	

428.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
429.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
430.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
431.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
432.	Inventory Control – Suspicious Order Policy	02/26/2016
433.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
434.	Deposition Transcript Excerpts of Anthony Mollica	01/04/2019
435.	Deposition Transcript Excerpts of Joseph Edward Miller	12/20/2018
436.	Deposition Transcript Excerpts of Joseph Edward Miller	12/20/2018
437.	Email Re: Daily HBC Suspicious Purchasing Report	01/10/2014
438.	Email Re: Daily HBC Suspicious Purchasing Report	09/23/2015
439.	Email re: Norco volume for store RX4031	07/08/2014
440.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
441.	Emails re: Gian Eagle / Buzzeo PDMA: SOM Services Proposal	10/01/2015
442.	Deposition Transcript Excerpts of James Tsipakis	12/13/2018
443.	Matthew Greimel Expert Report	05/10/2019
444.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018
445.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018
446.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018
447.	Report of Craig McCann, Appendix 9 at pp 151, 193	03/25/2019
448.	Report of Craig McCann, Appendix 9 at 3783, 3852	03/25/2019
449.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019

450.	Deposition Transcript Excerpts of Tom Nameth and Jason Briscoe	01/07/2019
451.	Deposition Transcript Excerpts of Jill Strang, Tom Nameth, and Jason Briscoe	01/03/2019
452.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018
453.	Deposition Transcript Excerpts of Jason Briscoe, Tom Nameth, and Jill Strang	12/06/2018
454.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
455.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
456.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
457.	21 C.F.R. § 1301.74	
458.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
459.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
460.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
461.	Deposition Transcript Excerpts of Peter Ratycz, Jill Strang, and Tom Nameth	12/21/2018
462.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018
463.	Deposition Transcript Excerpts of Jill Strang and Jason Briscoe	01/03/2019
464.	Deposition Transcript Excerpts of Jill Strang	01/03/2019
465.	Shipments Greater than .99% of AVG. Movement and Deposition Transcript Excerpts of Tom Nameth	
466.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
467.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
468.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
469.	Deposition Transcript Excerpts of Jason Briscoe	12/06/2018

470.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
471.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
472.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
473.	Deposition Transcript Excerpts of Tom Nameth, Jill Strang, and Jason Briscoe	01/07/2019
474.	Deposition Transcript Excerpts of Tom Nameth and Jason Briscoe	01/07/2019
475.	Email re: Controlled Substance Monitoring	10/23/2013
476.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
477.	Email about article: DEA Fines Coscto \$11.75M over lax US Pharmacy Controls and what it means for DDM	01/20/2017
478.	Deposition Transcript Excerpts of Jill Strang and Tom Nameth	01/03/2019
479.	Deposition Transcript Excerpts of Tom Nameth	01/07/2019
480.	Press Release	01/24/2013
481.	Press Release	06/15/2015
482.	Press Release	10/01/2013
483.	Kaufhold Deposition Exhibit 3	10/26/2018
484.	Woods Deposition Exhibit 12 [Allergan_MDL_ 02081243]	08/18/2009
485.	Woods Deposition Exhibit 13; [Allergan_MDL_02128514]	01/09/2019
486.	Woods Deposition Exhibit 12 [Allergan_MDL_ 02081243]	01/09/2019
487.	Omnicare Finasteride [Allergan_MDL_02128035]	02/11/2009
488.	Email re Suspicious Orders [Allergan_MDL_043233370]	08/24/2009
489.	Baran Deposition Excerpts	12/11/2018
490.	Woods Depostiion Exhibit 14 [Allergan_MDL_00490306]	01/09/2019

491.	Email re Opt-source Oxy IR Orders [Allergan_MDL_00665233]	03/24/2011
492.	Woods Deposition Exhibit 15	01/09/2019
493.	Incident Report	10/4/2012
494.	Woods Deposition Exhibit 16	01/09/2019
495.	Woods Deposition Excerpts	07/31/2012
496.	DEA Memo Distributor Briefing [US-DEA 00000001]	11/05/2012
497.	Clark Deposition Excerpts	12/07/2018
498.	Clark Deposition Excerpts	12/07/2018
499.	Woods Ex. 1 [Allergan_MDL_01844864]	01/09/2019
500.	Woods Depo Ex, 3 [Allergan_MDL_01839001]	01/09/2019
501.	2016 YTD Report [Allergan_MDL_02181123]	3/22/2016
502.	Woods Exh. 33 [Allergan_MDL_02187056]	01/09/2019
503.	Email re SOP Training [Allergan_MDL_01838989]	09/22/2004
504.	SOM Policy [Allergan_MDL_02146521]	07/19/2011
505.	SOM Policy [Allergan_MDL_1839002]	05/03/2004
506.	Call Center Operations Master Data Proc. [Allergan_MDL_01175574]	05/03/2004
507.	SOM Project Status review 11.8.2011 [Allergan_MDL_03368470]	11/08/2011
508.	Woods depo excerpts	01/09/2019
509.	Woods Ex. 35 [Allergan_MDL_03802654]	01/09/2019
510.	Woods Ex. 33 [Allergan_MDL_02187056]	01/09/2019
511.	Napoli Depo Ex. 1 [Allergan_MDL_0353513]	06/09/2011

512.	SOM Cloud Services Proposal [Allergan_MDL_02467540]	02/19/2015
513.	4.5.12 SOMS Presentation [Allergan_MDL_02468983]	04/05/2012
514.	Napoli Deposition Excerpts	01/17/2019
515.	Oxy Release Notification Alert [Allergan_MDL_01843335]	03/04/2011
516.	Buskey Expert Report	05/31/2019
517.	Call re DEA Next Steps [HSI-MDL-00620224]	05/30/2007
518.	Summary of DEA Meeting – Next Steps [CAH_MDL2804_02489199]	09/07/2007
519.	Email re CS Review Chart [HDA_MDL_000148603]	02/06/2008
520.	HDMA Best Practices [HDA_MDL_000148607]	01/31/2008

Dated: July 2, 2019

Respectfully submitted,

/s/ Paul J. Hanly, Jr.

Paul J. Hanly, Jr.  
SIMMONS HANLY CONROY  
112 Madison Avenue, 7<sup>th</sup> Floor  
New York, NY 10016  
(212) 784-6400  
(212) 213-5949 (fax)  
phanly@simmonsfirm.com

Joseph F. Rice  
MOTLEY RICE  
28 Bridgeside Blvd.  
Mt. Pleasant, SC 29464  
(843) 216-9000  
(843) 216-9290 (Fax)  
jrice@motleyrice.com

Paul T. Farrell, Jr., Esq.  
GREENE KETCHUM, LLP  
419 Eleventh Street  
Huntington, WV 25701

(304) 525-9115  
(800) 479-0053  
(304) 529-3284 (Fax)  
paul@greeneketchum.com

*Plaintiffs' Co-Lead Counsel*

Peter H. Weinberger (0022076)  
SPANGENBERG SHIBLEY & LIBER  
1001 Lakeside Avenue East, Suite 1700  
Cleveland, OH 44114  
(216) 696-3232  
(216) 696-3924 (Fax)  
pweinberger@spanglaw.com

*Plaintiffs' Liaison Counsel*

Hunter J. Shkolnik  
NAPOLI SHKOLNIK  
360 Lexington Ave., 11<sup>th</sup> Floor  
New York, NY 10017  
(212) 397-1000  
(646) 843-7603 (Fax)  
hunter@napolilaw.com

*Counsel for Plaintiff Cuyahoga County, Ohio*

Linda Singer  
MOTLEY RICE LLC  
401 9th St. NW, Suite 1001  
Washington, DC 20004  
(202) 386-9626 x5626  
(202) 386-9622 (Fax)  
lsinger@motleyrice.com

*Counsel for Plaintiff Summit County, Ohio*